Recommendations for rifampicin therapy of staphylococcal infection in infectious diseases society of America prosthetic joint infection guidelines are not supported by available literature

Clinical Infectious Diseases

Volumn 57, Issue 1, 2013, Pages 159-160

  Eisen, Damon P ^a   Denholm, Justin S ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; DAPTOMYCIN; FUSIDIC ACID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; HUMAN; JOINT PROSTHESIS; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

HUMANS; JOINT PROSTHESIS; PROSTHESIS-RELATED INFECTIONS;

EID: 84878840687     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit183     Document Type: Letter

References (9)

1. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1-25.
2. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537-41. (Pubitemid 28233008)
3. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14-34.
4. Sekiguchi J, Fujino T, Araake M, et al. Emergence of rifampicin resistance in methicillinresistant Staphylococcus aureus in tuberculosis wards. J Infect Chemother 2006; 12:47-50.
5. Tan CK, Lai CC, Liao CH, Lin SH, Huang YT, Hsueh PR. Increased rifampicin resistance in blood isolates of meticillin-resistant Staphylococcus aureus (MRSA) amongst patients exposed to rifampicin-containing antituberculous treatment. Int J Antimicrob Agents 2011; 37:550-3.
6. Eng RH, Smith SM, Buccini FJ, Cherubin CE. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother 1985; 15:201-7. (Pubitemid 15109085)
7. Lefebvre M, Jacqueline C, Amador G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillinresistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010; 36:542-4.
8. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999. Microb Drug Resist 2003; 9:155-60. (Pubitemid 36736233)
9. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5:231-49. (Pubitemid 43379622)